Introduction
============

Colorectal cancer (CRC) is the third most common malignant cancer and one of the main causes of cancer-related death worldwide. There are approximately 1.4 million newly diagnosed CRC patients each year, and their 5-year survival rate is not ideal.[@b1-cmar-10-6581] The bad prognosis of patients with CRC is largely due to the metastatic progression.[@b2-cmar-10-6581] Metastasis is a multi-link, multifactorial, continuous and complex process that is one of the basic biological characteristics of malignant tumors and a key factor in determining the prognosis of cancer.[@b3-cmar-10-6581]--[@b5-cmar-10-6581] In general, the metastatic process involves the spread of tumor cells, vascular invasion, lymph node metastasis and growth of new cancer cell colonies.[@b6-cmar-10-6581],[@b7-cmar-10-6581] CRC is one of the five leading causes of cancer-related death among both men and women in China.[@b8-cmar-10-6581] Currently, the incidence of CRC is still increasing in China, and approximately 25% of CRC patients have metastasized tumors prior to diagnosis.[@b9-cmar-10-6581],[@b10-cmar-10-6581] Therefore, it is necessary to identify effective predictors associated with CRC progression and metastasis, which may help patients choose appropriate treatments and monitoring.

CCBE1, which is located in human chromosomal region 18q21.32, encodes a highly conserved protein with EGF-like domain.[@b11-cmar-10-6581] Early studies found that CCBE1 not only regulated extracellular matrix remodeling and migration and multicellular organism development[@b12-cmar-10-6581],[@b13-cmar-10-6581] but also played an important role in the development of lymphatic vessels, angiogenic sprouting and lymphangiogenic budding from venous endothelium.[@b14-cmar-10-6581]--[@b20-cmar-10-6581] In the past few years, the role of CCBE1 in cancers is beginning to be reported. However, reports indicate that CCBE1 expression has different effects in different malignancies. Barton et al[@b21-cmar-10-6581] and Li et al[@b22-cmar-10-6581] supported CCBE1 as a potential tumor suppressor in ovarian cancer and lung cancer. Mesci et al[@b23-cmar-10-6581] and Mesci and Liu[@b24-cmar-10-6581] showed that in breast cancer CCBE1 is targeted by miR-330-3p, resulting in a more aggressive phenotype. However, Tian et al[@b25-cmar-10-6581] described CCBE1 as a tumor promoter in gastrointestinal stromal tumors (GISTs), which enhanced tumor angiogenesis. In addition, Guo et al[@b26-cmar-10-6581] and Zhang and Liu[@b27-cmar-10-6581] indicated that the increased expression of SLP-2 promoted the formation of lymph vessels and exacerbated lymphatic metastasis of rectal cancer via upregulation of CCBE1. Lymphatic metastasis and vascular invasion are the main means of CRC spread and can significantly affect the prognosis of patients.[@b28-cmar-10-6581]--[@b31-cmar-10-6581] However, less information was available for the prognostic value of CCBE1 in CRC.

In this study, we detected the expression of CCBE1 in 30 cases of fresh CRC tissues and paired adjacent normal (AN) tissues and tissue samples from 204 CRC cases analyzed for correlation between CCBE1 expression and clinicopathological features. Further, whether CCBE1 could be used as a potential prognostic biomarker for primary CRC patients after surgical resection was assessed.

Patients and methods
====================

Patients and samples
--------------------

Thirty cases of fresh CRC tissues and matched AN tissues were collected from the Department of General Surgery from January to December 2017. All tissues were freshly frozen in liquid nitrogen until quantitative real-time PCR (qRT-PCR) and Western blotting test. Furthermore, from January 2002 to September 2007, a total of 204 patients' CRC samples with detailed clinical records were collected and reassembled into multiple tissue arrays in our retrospective study. All samples were collected without chemotherapy, immunotherapy and radiotherapy before surgery from Xiangya Hospital. All cases were diagnosed independently by two pathologists and followed up regularly until December 2017. This study was approved by the ethics committee of Xiangya Hospital of Central South University. According to the Declaration of Helsinki, all patients and their families provided written informed consent and agreed to use their tissue samples in the study. Follow-up of all the patients was carried out based on the surveillance suggested in the guidelines.

RNA extraction and gene expression by qRT-PCR
---------------------------------------------

Total RNA from fresh CRC and AN tissues was extracted with the TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions. RNA quantity and quality were evaluated using a Nanodrop spectrophotometer (Thermo Fisher Scientific). RNA was reverse transcribed into cDNA by BeyoRT^™^ II First-Strand cDNA Synthesis Kit (Beyotime, Shanghai, China), and the expression of CCBE1 was measured using SYBR Green Master Mix (Beyotime) on the Applied Biosystems Quant-Studio^™^ 3 & 5 Real-Time PCR System (Thermo Fisher Scientific). The sequences of the primers used were listed as follows: CCBE1-F: 5′-TACCGATATGACCGGGAGAG-3′ and CCBE1-R: 5′-AGCTGCCCAAGGTATTGATG-3′; GADPH-F: 5′-GTCTCCTCTGACTTCAACAGCG-3′ and GADPH-R: 5′-ACCACCCTGTTGCTGTAGCCAA-3′. The experiments were repeated three times. The data were normalized to GAPDH expression and calculated as 2^−ΔΔCT^.

Western blot
------------

Proteins were extracted from fresh CRC and AN tissues using RIPA lysis buffer with protease inhibitors and quantified by BCA Protein Assay Kit (Beyotime). An amount of 30 µg per sample was separated by SDS-PAGE and then transferred to the polyvinylidene difluoride (PVDF) membrane (Hoff-man-La Roche Ltd., Basel, Switzerland). The membranes were blocked with 5% skimmed milk and incubated with CCBE1 (Affinity, Cincinnati, OH, USA; diluted 1:1,000) and GAPDH (Affinity; diluted 1:1,000) antibodies overnight at 4°C. The antigen--antibody complex on the membrane was detected with enhanced chemiluminescence reagents (Thermo Fisher Scientific).

Immunohistochemistry (IHC)
--------------------------

Tissue microarrays were constructed from a representative core from each CRC tissue and AN tissue. Tissue sections with diameters of 1.5 mm and 4 µm thicknesses were placed on slides coated with 3-aminopropyltriethoxysilane. Immunohistochemical staining for tissue was performed using the polymer horseradish peroxidase detection system (Zhongshan Goldenbridge Biotechnology, Beijing, China). All tissue microarrays were incubated with the CCBE1 antibody (diluted 1:200) overnight at 4°C. After incubation with secondary biotinylated antibody, sections were stained, the same length, with diaminobenzidine (DAB) and hematoxylin. The immunohistochemical staining intensity of CCBE1 was scored as negative (0), weak (1), moderate (2) and strong (3), and the percentage of positive cells was scored as 5% (0), 5--30% (1), 31--50% (2) and \>50% (3). The scores were calculated by multiplying these two values (ranging from 0 to 9). The protein expression in CRC specimens was divided into the low expression group (\<4) and the high expression group (≥4) for further analysis.[@b32-cmar-10-6581],[@b33-cmar-10-6581]

Statistical analyses
--------------------

All data were analyzed with IBM SPSS Statistics 22 Software (IBM Corporation, Armonk, NY, USA). Data were expressed as mean ± standard error of the mean (SEM) for at least three independent experiments. Quantitative data between groups were compared using the Student's *t*-test. Correlations between different CCBE1 expression levels were determined using Pearson's chi-squared test. Overall survival (OS) and disease-free survival (DFS) analyses were performed by the Kaplan--Meier method and log-rank test. Univariate and multivariate analyses were analyzed with Cox proportional hazard regression model to verify the independent risk factors. *P*-value of \<0.05 was defined as statistically significant.

Results
=======

Expression levels of CCBE1 in CRC patients
------------------------------------------

The expression of CCBE1 in 30 cases of fresh CRC tissues and matched AN tissues was detected by qRT-PCR, Western blotting and IHC. The qRT-PCR results indicated that CCBE1 mRNA level was significantly higher in CRC tissues compared with matched AN tissues (\[fold change {CRC/AN} \>2\] in 63.3% cases \[19/30\]; [Figure 1A](#f1-cmar-10-6581){ref-type="fig"}). Meanwhile, Western blotting results revealed that CCBE1 protein was highly expressed in most primary CRC tissues than in the matched AN tissues ([Figure 1B](#f1-cmar-10-6581){ref-type="fig"}). In addition, the immunohistochemical staining intensity of CCBE1 in liver metastatic CRC tissues is much stronger than that in paired primary CRC tissues and AN tissues ([Figure 1C](#f1-cmar-10-6581){ref-type="fig"}). These data indicate that CCBE1 is highly expressed in CRC tissues and may be associated with its invasion and metastasis.

CCBE1 expression correlates with clinicopathological features of CRC patients
-----------------------------------------------------------------------------

To analyze the association between CCBE1 and the clinicopathological features of CRC, we examined the expression of CCBE1 in 204 CRC tissue samples by IHC. As shown in [Figure 2](#f2-cmar-10-6581){ref-type="fig"}, the ICH staining intensity of CCBE1 was scored as negative (−), weak (+), moderate (++) and strong (+++), and the percentage of positive cells was scored as 5% (−), 5 −30% (+), 31 −50% (++) and \>50% (+++). The scores were calculated by multiplying these two values (ranging from 0 to 9). The protein expression in CRC specimens was divided into the low expression group (\<4) and the high expression group (≥4) for further analysis.[@b32-cmar-10-6581],[@b33-cmar-10-6581] The protein expression in CRC specimens was divided into the low expression group (91, 44.6%) and the high expression group (113, 55.4%). Pearson's chi-squared test analysis showed that CCBE1 expression was significantly correlated with tumor differentiation (*P*=0.003), TNM stage (*P*=0.009), lymph node metastasis (*P*\<0.001), vascular invasion (*P*=0.006), liver metastasis (*P*=0.010) and serum carcinoembryonic antigen (CEA; *P*=0.015) expression, but was not associated with gender, age, primary tumor location, tumor size, serum CA19-9 expression, or postoperative chemotherapy ([Table 1](#t1-cmar-10-6581){ref-type="table"}; *P*\>0.05).

High CCBE1 expression correlates with poor survival of CRC patients
-------------------------------------------------------------------

The correlation between CCBE1 expression and patients' OS and DFS was estimated by Kaplan--Meier analyses. Kaplan--Meier analyses showed that CRC patients with higher expression of CCBE1 had poor OS and DFS compared with patients with lower expression (*P*\<0.001 for both OS and DFS; [Figure 3A](#f3-cmar-10-6581){ref-type="fig"}); Moreover, tumor differentiation, lymph node metastasis, vascular invasion and liver metastasis were confirmed to be associated with patients' OS and DFS ([Tables 2](#t2-cmar-10-6581){ref-type="table"} and [3](#t3-cmar-10-6581){ref-type="table"}; [Figure 3B--D](#f3-cmar-10-6581){ref-type="fig"}; *P*\<0.01). Univariate and multivariate analyses were performed to determine independent prognostic factors for CRC patients after surgery. Univariate analyses showed that CCBE1 expression (*P*\<0.001 for OS and DFS), tumor differentiation (*P\<*0.001 for OS and DFS), lymph node metastasis (*P*\<0.001 for OS and DFS), vascular invasion (*P*\<0.001 for OS and DFS), liver metastasis (*P*\<0.001 for OS and DFS) and TNM stage (*P*=0.012 for OS, *P*=0.005 for DFS) were prognostic factors, and multivariate analyses showed that CCBE1 expression (*P*\<0.001 for OS, *P*=0.028 for DFS), tumor differentiation (*P*=0.001 for OS, *P\<*0.001 for DFS), lymph node metastasis (not significant \[NS\] for OS, *P*=0.044 for DFS), vascular invasion (*P*\<0.001 for OS, NS for DFS) were independent prognostic factors in CRC patients after surgery ([Tables 2](#t2-cmar-10-6581){ref-type="table"} and [3](#t3-cmar-10-6581){ref-type="table"}). In The Cancer Genome Atlas (TCGA) CRC data, the patients were divided into the low expression group and the high expression group according to the same median value. In TCGA database analysis, patients with high CCBE1 levels had a worse prognosis than patients with low CCBE1 levels (OS: log-rank *P*=6e-04, HR \[high\] =2.4, *P* \[HR\] =0.00084; DFS: log-rank *P*=0.0081, HR \[high\] =1.9, *P* \[HR\] =0.0093; [Figure 4](#f4-cmar-10-6581){ref-type="fig"}). These results fully demonstrated that CCBE1 expression was closely correlated with poor survival and could be used as a novel independent prognostic biomarker for CRC patients after surgery.

Discussion
==========

CRC is the third most common malignant cancer and one of the main causes of cancer-related death worldwide.[@b1-cmar-10-6581] The bad prognosis of patients with CRC is largely due to the metastatic progression.[@b2-cmar-10-6581] In general, the metastatic process involves the spread of tumor cells, vascular invasion, lymph node metastasis and growth of new cancer cell colonies.[@b2-cmar-10-6581],[@b4-cmar-10-6581],[@b5-cmar-10-6581],[@b7-cmar-10-6581],[@b8-cmar-10-6581],[@b34-cmar-10-6581] Therefore, it is necessary to identify effective predictors to help patients choose appropriate treatments and monitoring. As a newly discovered important lymphangiogenesis and pro-angiogenic factor, CCBE1 has received increasing attention in cancer research.[@b21-cmar-10-6581],[@b23-cmar-10-6581]--[@b27-cmar-10-6581] In this study, data analyzed from 30 fresh CRC tissues and paired AN tissues indicated that CCBE1 is highly expressed in CRC tissues and may be associated with tumor malignancy, invasion and metastasis. This result is consistent with the findings of Zhang and Liu[@b27-cmar-10-6581] and Tian et al,[@b25-cmar-10-6581] which showed that the upregulation of CCBE1 aggravates lymphatic metastasis of rectal cancer and enhances tumor angiogenesis of GISTs. However, CCBE1 is similar to other oncogenes, has tissue specificity and has different expression levels and effects in different tumors. For instance, Barton et al[@b21-cmar-10-6581] supported CCBE1 as a potential tumor suppressor in ovarian cancer, and Mesci et al[@b23-cmar-10-6581] showed that CCBE1 exerts a tumor suppressive effect in breast cancer by in vitro invasion assay of human breast cancer cell lines. In addition, lymphatic metastasis and vascular invasion are the main means of CRC spread and can significantly affect the prognosis of patients.[@b35-cmar-10-6581] Previous studies found that CCBE1 is a secreted molecule involved in lymphangiogenesis,[@b14-cmar-10-6581],[@b36-cmar-10-6581] and congenital CCBE1 mutations have been shown to cause Hennekam syndrome.[@b36-cmar-10-6581],[@b37-cmar-10-6581] To confirm the relationship between CCBE1 expression and prognosis and clinicopathological features of CRC, 204 cases of CRC tissues were stained to analyze. IHC results showed that high expression of CCBE1 was observed in 55.4% (113/204) CRC patients. Pearson's chi-squared test analysis showed that CCBE1 expression was significantly correlated with tumor differentiation, TNM stage, lymph node metastasis, vascular invasion, liver metastasis and serum CEA, but was not associated with gender, age, primary tumor location, tumor size, serum CA19-9 level or postoperative chemotherapy. The abovementioned results indicated that the expression level of CCBE1 was closely related to CRC invasion and metastasis. It is well known that tumor differentiation, lymph node metastasis, vascular invasion, organ metastasis and TNM staging are key factors influencing the progression and survival prognosis of CRC patients.[@b2-cmar-10-6581],[@b30-cmar-10-6581],[@b34-cmar-10-6581],[@b38-cmar-10-6581] In the present study, our data also indicated that tumor differentiation, lymph node metastasis, vascular invasion and liver metastasis were associated with patients' poor OS and DFS. Most importantly, we found that high expression of CCBE1 was significantly associated with CRC patients' poor OS and DFS, and OS analysis of 267 CRC patients from the TCGA database showed the same trend. Previous studies showed that the upregulation of CCBE1 was correlated with poorer survival of rectal cancer[@b26-cmar-10-6581] and GISTs,[@b25-cmar-10-6581] similar to our results. However, the tumor-promoting or tumor suppressor function of CCBE1 has background specificity, even in cancers of the same tissue origin. Mesci et al[@b23-cmar-10-6581] provided the first report on the loss of CCBE1 in breast cancer, and Barton et al[@b21-cmar-10-6581] described the loss of CCBE1 in ovarian cancers. Their results showed a correlation with poorer survival with lower CCBE1 expression, which is contrary to our results. Univariate and multivariate analyses showed that CCBE1 expression, tumor differentiation, lymph node metastasis and vascular invasion were independent prognostic factors in CRC patients after surgery. These results fully demonstrated that the presence of CCBE1 was closely correlated with poor survival and could be used as a novel independent prognostic biomarker for CRC patients after surgery. However, our study only initially assessed the clinical value of CCBE1 in CRC patients. To confirm the prognostic value of CCBE1 in CRC patients, further multicenter studies are needed to validate our observations.

Conclusion
==========

Our study suggests that CCBE1 is a highly expressed oncogene in CRC patients. High expression of CCBE1 is significantly related to tumor differentiation, TNM stage, lymph node metastasis, vascular invasion, liver metastasis, serum CEA and poor prognosis. In addition, our findings indicated that CCBE1 was closely correlated with poor OS and DFS and could be used as a novel independent prognostic biomarker for CRC patients after surgery. Of course, further investigations are needed to validate our findings.
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![CCBE1 expression in CRC patients.\
**Note:** The expression of CCBE1 was detected in 30 fresh CRC tissues and matched AN tissues by qRT-PCR (**A**), Western blotting (**B**) and IHC (**C**).\
**Abbreviations:** AN, adjacent normal; CRC, colorectal cancer; IHC, immunohistochemistry; qRT-PCR, quantitative real-time PCR.](cmar-10-6581Fig1){#f1-cmar-10-6581}

![CCBE1 expression was detected in CRC patients by immunohistochemical staining.\
**Notes:** (**A**) Thirty-seven cases of CCBE1 negative staining of CRC tissues accounted for 18.1%. (**B**) Fifty-four cases of CCBE1 weak staining (+) of CRC tissues accounted for 26.5%. (**C**) Sixty-four cases of CCBE1 moderate staining of CRC tissues accounted for 31.4%. (**D**) Forty-nine cases of CCBE1 strong staining of CRC tissues accounted for 24.0%. The protein expression in CRC specimens was divided into the low expression group (91, 44.6%) and the high expression group (113, 55.4%).\
**Abbreviation:** CRC, colorectal cancer.](cmar-10-6581Fig2){#f2-cmar-10-6581}

![Kaplan--Meier OS and DFS analyses of CRC.\
**Note:** Results indicated that CCBE1 expression (**A**), tumor differentiation (**B**), lymph node metastasis (**C**) and vascular invasion (**D**) were associated with CRC patients' prognosis (all *P*\<0.001).\
**Abbreviations:** CRC, colorectal cancer; DFS, disease-free survival; OS, overall survival.](cmar-10-6581Fig3){#f3-cmar-10-6581}

![Kaplan--Meier OS (**A**) and DFS (**B**) curves of the TCGA CRC cohort show that patients with high CCBE1 level had a worse prognosis than patients with low CCBE1 level (OS: log-rank *P*=6e-04, HR \[high\] =2.4, *P* \[HR\] =0.00084; DFS: log-rank *P*=0.0081, HR \[high\] =1.9, *P* \[HR\] =0.0093).\
**Abbreviations:** CRC, colorectal cancer; DFS, disease-free survival; OS, overall survival; TCGA, The Cancer Genome Atlas; TPM, transcripts per million.](cmar-10-6581Fig4){#f4-cmar-10-6581}

###### 

Correlations of CCBE1 expression with clinicopathological characteristics of CRC patients

  Clinicopathological variables    n     CCBE1        
  -------------------------------- ----- ------- ---- -------------
                                                      
  **Gender**                                          
  Male                             123   56      67   
  Female                           81    35      46   0.744
  **Age (years)**                                     
  ≤60                              84    41      43   
  \>60                             120   50      70   0.312
  **Primary tumor location**                          
  RC                               98    44      54   
  LC                               62    29      33   
  Rectal                           44    18      26   0.833
  **Tumor differentiation**                           
  Well                             73    42      31   
  Moderate                         84    37      47   
  Poor                             47    12      35   **0.003**
  **Tumor size (cm)**                                 
  ≤5                               81    39      42   
  \>5                              123   52      71   0.409
  **TNM stage**                                       
  I--II                            72    41      31   
  III--IV                          132   50      82   **0.009**
  **Lymph node metastasis**                           
  Presence                         85    15      70   
  Absence                          119   76      43   **\<**0.001
  **Vascular invasion**                               
  Presence                         63    19      44   
  Absence                          141   72      69   **0.006**
  **Liver metastasis**                                
  Presence                         59    18      41   
  Absence                          145   73      72   **0.010**
  **Serum CE**A                                       
  ≤5 ng/mL                         67    38      29   
  \>5 ng/mL                        137   53      84   **0.015**
  **Serum CA19-9**                                    
  ≤37 U/mL                         55    30      25   
  \>37 U/mL                        149   61      88   0.083
  **Postoperative chemotherapy**                      
  No                               35    17      18   
  Yes                              169   74      95   0.604

**Notes:** Low expression of CCBE1: IHC score \<4; high expression of CCBE1: IHC score ≥4. Significant results (*P*\<0.05) are given in bold.

**Abbreviations:** CEA, carcinoembryonic antigen; CRC, colorectal cancer; IHC, immunohistochemistry; LC, left-sided colon; RC, right-sided colon.

###### 

Univariable and multivariable analysis of OS and clinicopathological variables of CRC patients

  Clinicopathological variables    n     Univariable analysis   Multivariable analysis                          
  -------------------------------- ----- ---------------------- ------------------------ ---------------------- -------------
                                                                                                                
  **Gender**                                                                                                    
  Male                             123   1                                                                      
  Female                           81    1.148 (0.749--1.758)   0.527                                           NA
  **Age (years)**                                                                                               
  ≤60                              84    1                                                                      
  \>60                             120   1.300 (0.853--1.981)   0.222                                           NA
  **Primary tumor location**                                                                                    
  RC                               98    1                                                                      
  LC                               62    1.165 (0.904--1.502)   0.238                                           NA
  Rectal                           44                                                                           
  **Tumor differentiation**                                                                                     
  Well                             73    1                                               1                      
  Moderate                         84    2.287 (1.716--3.048)   **\<**0.001              1.656 (1.232--2.225)   **0.001**
  Poor                             47                                                                           
  **Tumor size (cm)**                                                                                           
  ≤5                               81    1                                                                      
  \>5                              123   1.318 (0.858--2.024)   0.208                                           NA
  **TNM stage**                                                                                                 
  I--II                            72    1                                                                      
  III--IV                          132   1.766 (1.130--2.758)   **0.012**                                       NS
  **Lymph node metastasis**                                                                                     
  Presence                         85    1                                                                      
  Absence                          119   0.222 (0.143--0.342)   **\<**0.001                                     NS
  **Vascular invasion**                                                                                         
  Presence                         63    1                                               1                      
  Absence                          141   0.235 (0.153--0.360)   **\<**0.001              0.397 (0.251--0.629)   **\<**0.001
  **Liver metastasis**                                                                                          
  Presence                         59    1                                                                      
  Absence                          145   0.242 (0.158--0.372)   **\<**0.001                                     NS
  **Serum CE**A                                                                                                 
  ≤5 ng/mL                         67    1                                                                      
  \>5 ng/mL                        137   1.267 (0.812--1.976)   0.297                                           NA
  **Serum CA19-9**                                                                                              
  ≤37 U/mL                         55    1                                                                      
  \>37 U/mL                        149   0.931 (0.591--1.466)   0.757                                           NA
  **Postoperative chemotherapy**                                                                                
  No                               35    1                                                                      
  Yes                              169   1.035 (0.611--1.753)   0.897                                           NA
  **CCBE1 expression**                                                                                          
  Low                              91    1                                               1                      
  High                             113   3.660 (2.271--5.900)   **\<**0.001              2.614 (1.594--4.288)   **\<**0.001

**Notes:** Bold values indicate statistical significance *P*\<0.05.

**Abbreviations:** CEA, carcinoembryonic antigen; CRC, colorectal cancer; LC, left-sided colon; NA, not applicable; NS, not significant; OS, overall survival; RC, right-sided colon.

###### 

Univariable and multivariable analysis of DFS and clinicopathological variables of CRC patients

  Clinicopathological variables    n     Univariable analysis   Multivariable analysis                          
  -------------------------------- ----- ---------------------- ------------------------ ---------------------- -------------
                                                                                                                
  **Gender**                                                                                                    
  Male                             123   1                                                                      
  Female                           81    1.257 (0.832--1.899)   0.278                                           NA
  **Age (years)**                                                                                               
  ≤60                              84    1                                                                      
  \>60                             120   1.337 (0.894--2.001)   0.158                                           NA
  **Primary tumor location**                                                                                    
  RC                               98    1                                                                      
  LC                               62    1.194 (0.938--1.519)   0.150                                           NA
  Rectal                           44                                                                           
  **Tumor differentiation**                                                                                     
  Well                             73    1                                               1                      
  Moderate                         84    2.538 (1.923--3.350)   **\<**0.001              1.868 (1.401--2.492)   **\<**0.001
  Poor                             47                                                                           
  **Tumor size (cm)**                                                                                           
  ≤5                               81    1                                                                      
  \>5                              123   1.099 (0.736--1.641)   0.643                                           NA
  **TNM stage**                                                                                                 
  I--II                            72    1                                                                      
  III--IV                          132   1.847 (1.203--2.837)   **0.005**                                       NS
  **Lymph node metastasis**                                                                                     
  Presence                         85    1                                               1                      
  Absence                          119   0.216 (0.142--0.331)   **\<**0.001              0.505 (0.260--0.982)   **0.044**
  **Vascular invasion**                                                                                         
  Presence                         63    1                                                                      
  Absence                          141   0.220 (0.145--0.333)   **\<**0.001                                     NS
  **Liver metastasis**                                                                                          
  Presence                         59    1                                                                      
  Absence                          145   0.225 (0.149--0.341)   **\<**0.001                                     NS
  **Serum CE**A                                                                                                 
  ≤5 ng/mL                         67    1                                                                      
  \>5 ng/mL                        137   1.264 (0.825--1.937)   0.282                                           NA
  **Serum CA19-9**                                                                                              
  ≤37 U/mL                         55    1                                                                      
  \>37 U/mL                        149   0.886 (0.575--1.363)   0.581                                           NA
  **Postoperative chemotherapy**                                                                                
  No                               35    1                                                                      
  Yes                              169   0.893 (0.552--1.444)   0.644                                           NA
  **CCBE1 expression**                                                                                          
  Low                              91    1                                               1                      
  High                             113   3.009 (1.942--4.661)   **\<**0.001              1.740 (1.060--2.857)   **0.028**

**Notes:** Bold values indicate statistical significance *P*\<0.05.

**Abbreviations:** CEA, carcinoembryonic antigen; CRC, colorectal cancer; DFS, disease-free survival; LC, left-sided colon; NA, not applicable; NS, not significant; RC, right-sided colon.
